POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Clinical trials for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug aims to free blood cancer patients from frequent transfusions
Disease control Recruiting nowThis study tests an experimental drug called DISC-0974 in about 150 adults with myelofibrosis or myelodysplastic syndrome who also have anemia. The goal is to see if the drug is safe and can help patients need fewer or no blood transfusions. The study is in early to mid stages an…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated May 26, 2026 08:23 UTC
-
New hope for myelofibrosis patients who fail standard therapy
Disease control Recruiting nowThis early-phase study tests a new daily pill, AJ1-11095, in adults with myelofibrosis (a rare bone marrow cancer) whose disease has not responded or has returned after standard JAK2 inhibitor treatment. The main goals are to check safety, find the best dose, and see if it can re…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE1 • Sponsor: Ajax Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 08:23 UTC
-
New hope for rare blood cancers: first human trial of PRT12396 begins
Disease control Recruiting nowThis early-stage study tests a new drug called PRT12396 in about 100 people with two rare blood cancers: polycythemia vera and myelofibrosis. The main goals are to find a safe dose and see if the drug can help control the disease. Participants must have a specific genetic mutatio…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
Blood cancer drug bomedemstat gets Long-Term safety check in 400 patients
Disease control Recruiting nowThis study is for people with certain blood cancers (like essential thrombocythemia or myelofibrosis) who are already doing well on the drug bomedemstat. It aims to collect long-term safety information and see how well the drug continues to work. About 400 participants will conti…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis study is a long-term registry for people with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Researchers will collect health records, surveys, and insurance data from 5,000 participants over at least five years to understand how the disease progresses an…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated May 26, 2026 08:31 UTC
-
New registry study aims to map Real-World care for myelofibrosis anemia
Knowledge-focused Recruiting nowThis study is a registry that will follow 200 people in Germany with myelofibrosis and anemia. It will collect information on which treatments are used, how well they work, and how patients feel. The goal is to better understand current care and outcomes, not to test a new drug.
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated May 26, 2026 08:28 UTC